UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 37

of 'Intraductal papillary mucinous neoplasm of the pancreas (IPMN): Evaluation and management'

37
TI
Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results.
AU
Baiocchi GL, Portolani N, Bertagna F, Gheza F, Pizzocaro C, Giubbini R, Giulini SM
SO
J Exp Clin Cancer Res. 2008;27:10. Epub 2008 Jun 10.
 
Although some clinical and radiological features may predict malignancy presence in intraductal papillary mucinous pancreas neoplasms, preoperative diagnosis remains difficult. In this study we present 7 patients with Intraductal Papillary Mucinous Neoplasm (IPMN) studied both with 18FDG-PET and magnetic resonance cholangiopancreatography (MRCP). A focal hypermetabolism was documented in 2 patients (the standardized uptake value in the neoplastic foci was 6.7 and 9), while absence of FDG uptake in the neoplasm area was recorded in the remaining 5 cases. Mean follow-up was 27 months (range 21-34). The final judgement was benign IPMN in 5 cases and malignant IPMN in 2. PET scan always correctly predicted the presence or absence of malignancy, while MRCP failed to detect malignancy in 3/7 cases. In conclusion, this preliminary experience suggests that 18FDG-PET may prove useful for malignancy detection in IPMN, improving differential diagnosis with benign intraductal papillary growth by functional data.
AD
Department of Medical and Surgical Sciences, Surgical Clinic, University of Brescia, Brescia, Italy. baioksurg@hotmail.com
PMID